Harbor Capital Advisors Inc. Sells 15,770 Shares of LeMaitre Vascular, Inc. $LMAT

Harbor Capital Advisors Inc. cut its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 70.8% in the third quarter, HoldingsChannel reports. The firm owned 6,512 shares of the medical instruments supplier’s stock after selling 15,770 shares during the period. Harbor Capital Advisors Inc.’s holdings in LeMaitre Vascular were worth $570,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Advisors Asset Management Inc. grew its position in shares of LeMaitre Vascular by 3.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock worth $341,000 after buying an additional 118 shares in the last quarter. Federated Hermes Inc. lifted its stake in LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after acquiring an additional 155 shares during the period. Johnson Investment Counsel Inc. grew its holdings in LeMaitre Vascular by 0.7% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 29,639 shares of the medical instruments supplier’s stock worth $2,462,000 after acquiring an additional 211 shares in the last quarter. Franklin Resources Inc. grew its holdings in LeMaitre Vascular by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 13,499 shares of the medical instruments supplier’s stock worth $1,121,000 after acquiring an additional 212 shares in the last quarter. Finally, HighTower Advisors LLC increased its position in LeMaitre Vascular by 4.2% during the 1st quarter. HighTower Advisors LLC now owns 5,920 shares of the medical instruments supplier’s stock valued at $497,000 after purchasing an additional 237 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $83.78 on Monday. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $105.55. The business’s fifty day simple moving average is $86.00 and its 200-day simple moving average is $87.30. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The company has a market cap of $1.90 billion, a PE ratio of 36.11, a PEG ratio of 2.07 and a beta of 0.68.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The firm had revenue of $61.05 million for the quarter, compared to the consensus estimate of $62.18 million. During the same period in the previous year, the business earned $0.49 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th were issued a dividend of $0.20 per share. The ex-dividend date was Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s dividend payout ratio is 34.48%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on LMAT shares. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research report on Monday, November 10th. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 22nd. Wells Fargo & Company cut their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.